Related Disorder

Lipid Metabolism Overview In addition to abnormalities in glucose metabolism and lipodystrophy, HIV-infected patients often develop disturbances in lipid metabolism. The pattern of dyslipidemia observed in these patients is similar to that observed in the metabolic syndrome in non-HIV-infected individuals and consists of elevated serum triglyceride levels and decreased high-density lipoprotein cholesterol (HDL) levels, along

OverviewThe effects of ARV medications on glucose metabolism may be mediated by: (1) the decrease in viremia, improved immune function, and restitution to health; (2) a direct impact on peripheral insulin sensitivity and pancreatic β-cell function; (3) the development of lipodystrophy (peripheral lipoatrophy and/or central fat accumulation); or (4) impaired mitochondrial function. In vitro studies

OverviewThe term “lipodystrophy” is non-specific and has been used to describe lipoatrophy alone, fat accumulation alone, or a combination of the two. Most researchers agree that the characteristic feature is subcutaneous  fat loss, with or without concomitant fat accumulation (Fig. 38.3). The presence of lipodystrophy may affect glucose and lipid metabolism, decrease compliance with ARV

Since the introduction of highly active antiretroviral therapy (HAART) more than a decade ago, there has been a dramatic improvement in the morbidity and mortality associated with human immunodeficiency virus (HIV) infection and AIDS. As survival has improved, a constellation of metabolic and morphologic abnormalities, often referred to as the HIV-associated lipodystrophy syndrome, has become

The reported prevalence of OSAH in the United States has varied from 1 to 25%. While many studies that have reported prevalence of OSAH have included patients with moderate to severe obesity (often with BMI in excess of 40 kg/m2) the prevalence of OSAH in the mildly obese was unknown, until recently. A study conducted